Abstract:Hany SM Ali, 1, 2 Ahmed F Hanafy, 3 Rawan Bafail, 1 Hamad Alrbyawi, 1 Marey Almaghrabi, 1 Yaser M Alahmadi, 4 Samar El Achy 5 1 Department of Pharmaceutics and Pharmaceutical Industries, College of Pharmacy, Taibah University, Madinah, Al-Madinah Al-Munawwarah, Saudi Arabia; 2 Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt; 3 Research and Development Department, Al Andalous Pharmaceutical Industries, Giza, Egypt; 4 Department of Pharmacy Practice, College of Pharmacy, Taibah University, Madinah, Al-Madinah Al-Munawarah, 30001, Saudi Arabia; 5 Department of Anatomical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt Correspondence: Hany SM Ali, Email , Background: Budesonide (BUD) is a BCS class II medication with poor water solubility and limited oral bioavailability. In this study, innovative solid self-microemulsifying drug delivery systems (BUD-SMEDDS) were developed for effective local management of distal ulcerative colitis (UC). Methods: Based on solubility and emulsification tests, the components of the self-microemulsifying drug delivery system (SMEDDS) were CapryolTM 90, Tween 80, and Transcutol HP. The impacts of BUD-SMEDDS ingredients (as inputs) on the average globule size (AGS), polydispersity index (PDI), and self-emulsification time (SET) as responses were investigated using the Box–Behnken design methodology. Solid rectal systems were then fabricated using the optimized values of SMEDDS components in Lutrol ® bases. The developed systems were evaluated for in vitro characteristics and in vivo efficacy using a rat colitis model. Results: For all responses, the greatest impact was attributed to the oil content of SMEDDS. An optimized BUD-SMEDDS with AGS of 33 ± 2.9 nm, PDI of 0.29 ± 0.03 and SET of 25 ± 2.5 s) was selected for rectal formulations. The developed formulations demonstrated acceptable physical characteristics and mucoadhesive abilities. Differential scanning calorimetric (DSC) analysis revealed the absence of BUD crystallinity in the SMEDDS formulations. The drug release patterns could be regulated by selecting the grade and composition of the incorporated Lutrols. Clinical and histopathological assessments revealed considerable improvements in animals treated with BUD-SMEDDS formulations. Conclusion: Overall findings confirmed the superior capability of solid SMEDDS as BUD carriers to manage distal colitis in tested animals. Keywords: Budesonide, SMEDDS, Ulcerative colitis, Box Behnken design, efficacy Ulcerative colitis (UC) is a chronic inflammatory GIT disorder of unknown pathogenesis that affects the colon and rectum. 1 UC is characterized by intermittent flares of active disease with diarrhea, rectal bleeding, and rectal urgency broken by periods of remission. 2 Distal forms of UC include ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS) are found in nearly 50% of UC patients. 3 Immunosuppressive drugs, anti-TNF, and, more recently, anti-integrin therapies are commonly used to treat moderate to severe UC. 4 Oral corticosteroids are effective in treating acute flares but have little effects on sustaining remission. 5 Nonetheless, caution is required to avoid unwanted systemic effects. 6 Budesonide is one of the potent corticosteroids used in colitis management. 7 Consistent with the biopharmaceutics classification system, budesonide is a class II medication (log p = 3.2) with poor water solubility (28 μg/mL). 8–10 When used as a native form, BUD is quickly absorbed in the proximal gastrointestinal tract and subjected to extensive first-pass metabolism leading to a limited systemic bioavailability (6–8%). 9,11 This poses a challenge for its use in UC where delivery in sufficient concentrations to the site of inflammation is crucial. Topical treatment with BUD enema has been studied for the management of active distal UC. 12 However, many patients were found to have problems to retain the liquid enemas. To overcome this problem, rectal foams have also been developed. Small volumes of foam with high viscosity may favor retention and acceptance relative to the administration of high volumes of liquid enema. 13 However, adverse effects like decreased blood cortisol, adrenal insufficiency, and nausea were reported with administration of rectal foams. 14 Self-microemulsifying drug delivery systems (SMEDDS) are valuable for addressing the problems of formulating drugs with limited water solubility. In SMEDDS, isotropic mixtures of oils, surfactants, and co-surfactant -Abstract Truncated-

Design, Development and In vivo Evaluation of Core in Cup Tablets of Budesonide

Colon Delivery of Budesonide: Evaluation of Chitosan–Chondroitin Sulfate Interpolymer Complex

Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis

Preparation of budesonide–dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis

Preparation and Characterization of a Novel Multiparticulate Dosage Form Carrying Budesonide-Loaded Chitosan Nanoparticles to Enhance the Efficiency of Pellets in the Colon

Caffeic Acid-Conjugated Budesonide-Loaded Nanomicelle Attenuates Inflammation in Experimental Colitis

Formulation and development of novel Sulfasalazine bilayer tablets for the treatment of arthritis associated with IBD: In-vitro and In-vivo Investigations

Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial

Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment

Core-shell tablets designed for modified and sequential release of ibuprofen and rabeprazole

Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis

Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery

The Design of Novel 3D-Printed, Moulded, and Oral Viscous Budesonide Formulations for Paediatrics: A Comparative Evaluation of Their Mucoadhesive Properties

Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model

Formulation and optimization of a single-layer coat for targeting budesonide pellets to the descending Colon

Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases

Development of a Curcumin-Loaded Polymeric Microparticulate Oral Drug Delivery System for Colon Targeting by Quality-by-Design Approach

Design of colon-targeted drug delivery of dexamethasone: Formulation and in vitro characterization of solid dispersions

Budesonide Induces Favourable Histologic and Symptomatic Recovery in Patients with Non-responsive and Refractory Coeliac Disease When Given in an Open Capsule Format

Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression

Clinical Pharmacokinetics of Inhaled Budesonide